Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.

  title={Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.},
  author={Frank-Jan H. Drost and Dani{\"e}l F. Osses and Daan Nieboer and Chris H. Bangma and Ewout Willem Steyerberg and Monique J. Roobol and Ivo G. Schoots},
  journal={European urology},

Figures and Tables from this paper

Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.

MRI with only targeted biopsy was noninferior to systematic TRUS biopsies in the detection of International Society of Urological Pathology grade group (GG) 2 or greater prostate cancer.

Comparison of MRI- and TRUS-Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy-Naive Men: A Systematic Review and Meta-Analysis.

Evaluating whether mpMRI-informed TGBX has superior diagnosis rates of any-, CS-, high-grade (HG)-, and clinically insignificant (CI)-PCa compared to SBX in biopsy-naive men found it results in a significantly higher diagnosis rate of any, CS, and HG-PCa.

In-bore MRI targeted biopsy

Multiparametric Magnetic Resonance Imaging (mpMRI) has transformed the diagnostic pathway of PCa, not only as an imaging method for detecting suspicious lesions, but also as an intraprocedural guidance for Target Biopsy (MRI-TBx), thus bridging the diagnostic gap.

Developments in MRI-targeted prostate biopsy.

MRI-targetedBiopsy in selected men with positive MRI offers a number of benefits over systematic biopsy in all men, and as such, may emerge as the new standard of care for the diagnosis of clinically significant prostate cancer.

mpMRI-targeted biopsy versus systematic biopsy for clinically significant prostate cancer diagnosis: a systematic review and metaanalysis.

MRI-TB found more csPCa than SB in patients with suspected PCa in both scenarios, naïve and repeat biopsies, but more studies comparing those methods are warranted before any recommendation on this topic.

An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies

This study shows that performing TBx with ipsilateral SBx and omitting contralateral SBx is the optimal biopsy strategy in patients with a unilateral MRI lesion.

A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk.

A contemporary systematic review and meta-analysis of contemporary studies shows that bpMRI offers comparable test accuracies to mpMRI in detecting prostate cancer, but heterogeneity does not allow definitive recommendations to be made.



Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

The diagnostic accuracy of the index tests MRI only, MRI-targeted biopsy, the MRI pathway and systematic biopsy as compared to template-guidedBiopsy as the reference standard in detecting clinically significant prostate cancer as the target condition was determined.

MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis

The use of risk assessment with MRI before biopsy and MRI‐targeted biopsy was superior to standard transrectal ultrasonography–guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously.

The value of magnetic resonance imaging and ultrasonography (MRI/US)‐fusion biopsy platforms in prostate cancer detection: a systematic review

Although MRI/US‐fusion TB has proved its value in men with prior negative biopsies, general use of this technique in diagnosing prostate cancer should only be performed after critical consideration, andMRI/US fusion‐guided TBs tended to give higher CDRs for clinically significant prostate cancers in the authors' analysis.